FDA Approves Astellas' Vaprisol(R) (Conivaptan Hydrochloride Injection) Premixed In 5% Dextrose For The Treatment Of Hyponatremia

Astellas Pharma US, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved a new premixed formulation of Vaprisol: Vaprisol(R) (conivaptan hydrochloride injection) Premixed in 5% Dextrose. Discovered and developed by Astellas, Vaprisol, an arginine vasopressin (AVP) receptor antagonist, is the first and only approved drug indicated for the treatment of both euvolemic and hypervolemic hyponatremia in hospitalized patients.